1
|
Wang J, Wang Y, Li Y, Yang L, Sun B, Zhang Y, Xu Y, Yan X. l-Arginine treatment maintains postharvest quality in blueberry fruit by enhancing antioxidant capacity during storage. J Food Sci 2023; 88:3666-3680. [PMID: 37477270 DOI: 10.1111/1750-3841.16710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 06/22/2023] [Accepted: 07/05/2023] [Indexed: 07/22/2023]
Abstract
The postharvest quality of blueberry fruit is largely limited by deterioration. l-arginine (Arg) is a functional nontoxic amino acid with high biological activities. This study investigated the positive effects and the underlying mechanism of Arg treatment on the quality of postharvest blueberries. Arg effectively mitigated fruit decay and improved the quality of blueberries, including weight loss, firmness, and soluble solid content. Mechanistically, Arg-mediated activation of the anti-oxidative defense system reduced reactive oxygen species-mediated oxidative damage. Moreover, Arg treatment decreased the activities and gene expression of phospholipase D, lipoxygenase, and lipase-inhibiting membrane lipid peroxidation during the prolonged storage of blueberries. Meanwhile, Arg treatment increased nitric oxide (NO) content and NO synthase activity. Furthermore, correlation and principal component analyses revealed the enhancement of Arg treatment on antioxidant capacity. This study suggests that Arg treatment can maintain the postharvest quality of blueberries by improving antioxidant capacity.
Collapse
Affiliation(s)
- Jiaqi Wang
- College of Food Science, Shenyang Agricultural University, Shenyang, P. R. China
- Key Laboratory of Protected Horticulture (Shenyang Agricultural University), Ministry of Education, Shenyang, P. R. China
| | - Yajuan Wang
- Key Laboratory of Protected Horticulture (Shenyang Agricultural University), Ministry of Education, Shenyang, P. R. China
| | - Yuxuan Li
- College of Food Science, Shenyang Agricultural University, Shenyang, P. R. China
- Key Laboratory of Protected Horticulture (Shenyang Agricultural University), Ministry of Education, Shenyang, P. R. China
| | - Ling Yang
- College of Food Science, Shenyang Agricultural University, Shenyang, P. R. China
- Key Laboratory of Protected Horticulture (Shenyang Agricultural University), Ministry of Education, Shenyang, P. R. China
| | - Bingxin Sun
- College of Food Science, Shenyang Agricultural University, Shenyang, P. R. China
| | - Yunhe Zhang
- College of Food Science, Shenyang Agricultural University, Shenyang, P. R. China
| | - Yufeng Xu
- College of Food Science, Shenyang Agricultural University, Shenyang, P. R. China
| | - Xuerui Yan
- College of Food Science, Shenyang Agricultural University, Shenyang, P. R. China
- Key Laboratory of Protected Horticulture (Shenyang Agricultural University), Ministry of Education, Shenyang, P. R. China
| |
Collapse
|
2
|
Venkitachalam R, Szabo A, Guru Murthy GS. Population-Level Outcomes of Pediatric Acute Promyelocytic Leukemia in the United States. J Pediatr 2020; 223:114-119.e5. [PMID: 32482395 DOI: 10.1016/j.jpeds.2020.04.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 03/04/2020] [Accepted: 04/02/2020] [Indexed: 12/16/2022]
Abstract
OBJECTIVE To determine whether the population level outcomes of pediatric acute promyelocytic leukemia have improved over time. STUDY DESIGN We conducted a retrospective analysis of the Surveillance Epidemiology and End Results database for patients with acute promyelocytic leukemia, up to 20 years of age, diagnosed between 1976 and 2016 and actively followed. Patients were stratified based on their period of diagnosis (1976-1989, 1990-1999, 2000-2009, 2010-2016) to assess the temporal trends in overall survival and early mortality. RESULTS A total of 553 patients with a median age of 15 years (range, 0-20 years) were included. The 5-year overall survival increased significantly over time (by 22.6% from 1976 to 1989; by 59.2% from 1990 to 1999; by 77.7% from 2000 to 2009; and by 88.9% from 2010 to 2016; P < .001). Early mortality showed an improvement over time in the most recent cohort (by 14% from 1976 to 1989; by 13.5% from1990 to 1999; by 13.3% 2000 to 2009; and by 7.2% from 2010 to 2016) after adjusting for other demographic characteristics in a logistic regression model. On multivariate analysis of overall survival, diagnosis in the earlier time periods was associated with higher mortality as compared with the 2010-2016 period. Age, sex, and race/ethnicity were not significant predictors of overall survival. CONCLUSIONS Outcomes of pediatric acute promyelocytic leukemia have continued to improve over time at the population level.
Collapse
Affiliation(s)
| | - Aniko Szabo
- Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI
| | | |
Collapse
|
3
|
Czogała M, Pawińska-Wa Sikowska K, Ksia Żek T, Sikorska-Fic B, Matysiak M, Rodziewicz-Konarska A, Chybicka A, Skalska-Sadowska J, Wachowiak J, Muszyńska-Rosłan K, Krawczuk-Rybak M, Grabowski D, Kowalczyk J, Zielezińska K, Urasiński T, Tomaszewska R, Szczepański T, Karpińska-Derda I, Woszczyk M, Pohorecka J, Karolczyk G, Młynarski W, Mycko K, Badowska W, Skoczeń S, Balwierz W. Treatment Outcome and the Genetic Characteristics of Acute Promyelocytic Leukemia in Children in Poland From 2005 to 2018. Front Pediatr 2020; 8:86. [PMID: 32266181 PMCID: PMC7100382 DOI: 10.3389/fped.2020.00086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Accepted: 02/20/2020] [Indexed: 11/24/2022] Open
Abstract
Background: The aim of the study was to analyze the treatment outcome and genetic characteristics of acute promyelocytic leukemia (APL) in children in Poland from 2005 to 2018. Methods: All 41 patients diagnosed with APL in Poland during the analysis period were eligible for the study. In period I (2005-2015), 33 patients were treated with chemotherapy and all-trans retinoic acid (ATRA), and in period II (2015-2018), 3 patients (high risk) received induction chemotherapy with ATRA and arsenic trioxide (ATO), and 5 patients (standard risk) received ATRA and ATO without chemotherapy. Results: Probability of 5-years overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) was 0.819 ± 0.069, 0.831 ± 0.063, and 0.961 ± 0.037, respectively, in the whole cohort. Four (11%) early deaths were observed. One patient died of severe infection in the course of disease progression. Relapse occurred in one patient, who died finally because of disease progression. All events occurred in the patients from period I. Variant APL was identified in one patient (successfully treated with chemotherapy with ATRA) and complex translocation in one patient (the only patient with relapse). Additional chromosomal aberrations were found in 26% of patients and FLT3-ITD mutation was detected in 44% of patients; none of those changes influenced clinical outcome. Conclusion: Treatment outcome in the analyzed group is similar to the results reported by other study groups. The main cause of death was coagulation disorders in the early stage of disease. Early, accurate diagnosis followed by specific treatment enables the reduction in the number of early deaths.
Collapse
Affiliation(s)
- Małgorzata Czogała
- Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.,Department of Pediatric Oncology and Hematology, University Children Hospital, Krakow, Poland
| | - Katarzyna Pawińska-Wa Sikowska
- Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.,Department of Pediatric Oncology and Hematology, University Children Hospital, Krakow, Poland
| | - Teofila Ksia Żek
- Department of Pediatric Oncology and Hematology, University Children Hospital, Krakow, Poland.,Department of Medical Genetics, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland
| | - Barbara Sikorska-Fic
- Department of Pediatrics, Hematology and Oncology, Medical University of Warsaw, Warsaw, Poland
| | - Michał Matysiak
- Department of Pediatrics, Hematology and Oncology, Medical University of Warsaw, Warsaw, Poland
| | - Anna Rodziewicz-Konarska
- Department of Bone Marrow Transplantation, Pediatric Oncology and Hematology, Medical University of Wroclaw, Wroclaw, Poland
| | - Alicja Chybicka
- Department of Bone Marrow Transplantation, Pediatric Oncology and Hematology, Medical University of Wroclaw, Wroclaw, Poland
| | - Jolanta Skalska-Sadowska
- Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznan, Poland
| | - Jacek Wachowiak
- Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznan, Poland
| | | | - Maryna Krawczuk-Rybak
- Department of Pediatric Oncology and Hematology, Medical University of Bialystok, Bialystok, Poland
| | - Dominik Grabowski
- Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland
| | - Jerzy Kowalczyk
- Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland
| | - Karolina Zielezińska
- Department of Pediatrics, Hematology and Oncology, Pomeranian Medical University, Szczecin, Poland
| | - Tomasz Urasiński
- Department of Pediatrics, Hematology and Oncology, Pomeranian Medical University, Szczecin, Poland
| | - Renata Tomaszewska
- Department of Pediatrics Hematology and Oncology, Medical University of Silesia, Zabrze, Poland
| | - Tomasz Szczepański
- Department of Pediatrics Hematology and Oncology, Medical University of Silesia, Zabrze, Poland
| | | | - Mariola Woszczyk
- Department of Pediatrics, Hematology and Oncology, City Hospital, Chorzów, Poland
| | - Joanna Pohorecka
- Paediatric Department of Hematology and Oncology, Regional Polyclinic Hospital in Kielce, Kielce, Poland
| | - Grażyna Karolczyk
- Paediatric Department of Hematology and Oncology, Regional Polyclinic Hospital in Kielce, Kielce, Poland
| | - Wojciech Młynarski
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland
| | - Katarzyna Mycko
- Department of Pediatrics and Hematology and Oncology, Province Children's Hospital, Olsztyn, Poland
| | - Wanda Badowska
- Department of Pediatrics and Hematology and Oncology, Province Children's Hospital, Olsztyn, Poland
| | - Szymon Skoczeń
- Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.,Department of Pediatric Oncology and Hematology, University Children Hospital, Krakow, Poland
| | - Walentyna Balwierz
- Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.,Department of Pediatric Oncology and Hematology, University Children Hospital, Krakow, Poland
| |
Collapse
|
5
|
Freedman JL, Faerber J, Kang TI, Dai D, Fisher BT, Huang YS, Li Y, Aplenc R, Feudtner C. Predictors of antiemetic alteration in pediatric acute myeloid leukemia. Pediatr Blood Cancer 2014; 61:1798-805. [PMID: 24939039 PMCID: PMC4141025 DOI: 10.1002/pbc.25108] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Accepted: 04/28/2014] [Indexed: 11/07/2022]
Abstract
BACKGROUND Better knowledge of patient and cancer treatment factors associated with nausea/vomiting (NV) in pediatric oncology patients could enhance prophylaxis. We aimed to describe such factors in children receiving treatment for acute myeloid leukemia (AML). METHODS Retrospective longitudinal cohort study of 1,668 hospitalized children undergoing treatment for AML from the Pediatric Health Information System database (39 hospitals, 1999-2010). Antiemetic alteration, which included switch (a change in prescribed 5-HT₃ receptor antagonists) and rescue (receipt of an adjunct antiemetic), were first validated and then used as surrogates of problematic NV. Logistic and negative binomial regression modeling were used to test whether patient characteristics were associated with problematic NV. RESULTS Increasing age is associated with greater odds of experiencing antiemetic switch and higher relative rate of antiemetic rescue. Within a treatment cycle, each consecutive inpatient chemotherapy day decreased the likelihood of requiring antiemetic alteration. Each consecutive inpatient-day post-chemotherapy was associated with decreased need for switch, but increased need for rescue. Subsequent cycles of AML therapy were associated with lower odds of antiemetic switch on both chemotherapy and non-chemotherapy days, a lower rate of antiemetic rescue on chemotherapy days, and an increased rate of rescue on non-chemotherapy days. CONCLUSION In pediatric patients with AML, increasing age is strongly associated with greater antiemetic alteration. Antiemetic alteration occurs early in treatment overall, and early within each admission. While additional cycles of therapy are associated with less alteration overall, there is persistent rescue in the days after chemotherapy, suggesting additional etiologies of NV in pediatric cancer patients.
Collapse
Affiliation(s)
- Jason L. Freedman
- Division of Oncology, The Children’s Hospital of Philadelphia, Philadelphia, USA,Corresponding author: Jason L. Freedman, MD, MSCE, The Children’s Hospital of Philadelphia, 3501 Civic Center Boulevard, CTRB 10207, Philadelphia, PA 19104, Phone: 267-425-5822, Fax: 215-590-7544,
| | - Jennifer Faerber
- Division of General Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, USA
| | - Tammy I. Kang
- Divisions of Oncology and Palliative Care, The Children’s Hospital of Philadelphia, Philadelphia, USA
| | - Dingwei Dai
- Center for Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, USA
| | - Brian T. Fisher
- Division of Infectious Diseases/Center for Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia/University of Pennsylvania, Philadelphia, USA
| | - Yuan-Shung Huang
- Center for Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, USA
| | - Yimei Li
- Division of Oncology/Center for Clinical Epidemiology & Biostatistics, The Children’s Hospital of Philadelphia/University of Pennsylvania, Philadelphia, USA
| | - Richard Aplenc
- Division of Oncology/Center for Clinical Epidemiology & Biostatistics, The Children’s Hospital of Philadelphia/University of Pennsylvania, Philadelphia, USA
| | - Chris Feudtner
- Division of General Pediatrics/Center for Pediatric Clinical Effectiveness/Center for Clinical Epidemiology & Biostatistics, The Children’s Hospital of Philadelphia/University of Pennsylvania, Philadelphia, USA
| |
Collapse
|